Сomparative Evaluation of the Efficacy of Topical Treatment of Acute Rhinosinusitis and Adenoiditis in Children with Recurrent Infections After the Coronavirus Disease (COVID-19)
The frequency of acute respiratory infections varies greatly in children and may reach up to 15 episodes per year. Due to the spreading of the Delta variant of the SARS-CoV-2 virus, children attending preschool institutions are particularly exposed to risk of developing bacterial infections, such as rhinosinusitis and adenoiditis. We carried out a comparative analysis of the efficacy of topical antibiotic treatment of acute rhinosinusitis combined with adenoiditis after the novel coronavirus infection COVID-19 in children with recurrent infections using framycetin in the form of a dosed spray or in a bottle. The study included 129 patients aged 3 to 6 years with acute rhinosinusitis combined with adenoiditis as complications of COVID-19. Patients who received topical antibacterial treatment with framycetin in the form of a dosed spray demonstrated an improvement in the aeration of the paranasal sinuses and disappearance of discharge from the nasal cavity three days earlier than those who used framycetin in the form of a bottle. The need for systemic antibiotic treatment occurred in 3.07 and 10.9% of all cases, respectively. Thus, topical antibacterial treatment with framycetin in the form of a dosed spray in cases of acute rhinosinusitis in combination with adenoiditis as complications of COVID-19 allows to achieve optimal distribution of the drug agent in the posterior parts of the nasal cavity on the surface tissue of the pharyngeal tonsil, leading to a decrease in its size by reducing the inflammation in it, thereby improving the ventilation of the paranasal sinuses.